PureTech Health plc (NASDAQ:PRTC) Short Interest Up 18.9% in October

PureTech Health plc (NASDAQ:PRTC) was the target of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 6,300 shares, an increase of 18.9% from the October 15th total of 5,300 shares. Based on an average trading volume of 5,200 shares, the short-interest ratio is presently 1.2 days.

PureTech Health Trading Up 4.1 %

PRTC traded up $0.89 on Friday, hitting $22.82. 3,509 shares of the company’s stock were exchanged, compared to its average volume of 4,806. PureTech Health has a fifty-two week low of $17.08 and a fifty-two week high of $34.00. The firm has a 50-day moving average price of $20.41 and a 200-day moving average price of $23.48.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PRTC. Leerink Partners started coverage on shares of PureTech Health in a research report on Monday, September 9th. They issued an “outperform” rating and a $45.00 target price on the stock. Leerink Partnrs upgraded PureTech Health to a “strong-buy” rating in a research report on Monday, September 9th.

Hedge Funds Weigh In On PureTech Health

An institutional investor recently bought a new position in PureTech Health stock. AWM Investment Company Inc. acquired a new stake in PureTech Health plc (NASDAQ:PRTC) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 6,900 shares of the company’s stock, valued at approximately $197,000. 0.04% of the stock is owned by hedge funds and other institutional investors.

PureTech Health Company Profile

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.